{"id":967339,"date":"2026-05-27T08:04:39","date_gmt":"2026-05-27T12:04:39","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/coya-therapeutics-to-present-alstars-trial-design-at-the-5th-als-drug-development-summit\/"},"modified":"2026-05-27T08:04:39","modified_gmt":"2026-05-27T12:04:39","slug":"coya-therapeutics-to-present-alstars-trial-design-at-the-5th-als-drug-development-summit","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/coya-therapeutics-to-present-alstars-trial-design-at-the-5th-als-drug-development-summit\/","title":{"rendered":"Coya Therapeutics to Present ALSTARS Trial Design at the 5th ALS Drug Development Summit"},"content":{"rendered":"

<\/p>\n

Coya Therapeutics to Present ALSTARS Trial Design at the 5th ALS Drug Development Summit<\/b><\/p>\n

HOUSTON–(BUSINESS WIRE<\/a>)–Coya Therapeutics, Inc.<\/a> (NASDAQ: COYA) (\u201cCoya\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in patients with neurodegenerative disorders, announces that the Company will present an overview of the ongoing ALSTARS trial<\/a>, outlining its design and approach to targeting neuroinflammation, at the 5th ALS Drug Development Summit<\/a> which will take place June 2\u20134, 2026, in Boston, MA.<\/p>\n

\nThe details for the poster presentation, which will be presented by Tyrell Simkins, D.O., Ph.D., Senior Director, Clinical Development, are below:<\/p>\n

Poster Title<\/b>: ALSTARS: A Precision Immunomodulatory Phase 2 Trial of COYA 302 Targeting Regulatory T Cells and Neuroinflammation in ALS
\n
Authors<\/b>: Tyrell J. Simkins, DO, PhD; Fred Grossman, DO; Stanley Appel, MD; Karen King, MS; and James D. Berry, MD
\n
Date of Presentation<\/b>: Wednesday, June 3, 2026, 4:45 PM ET<\/p>\n

About Coya Therapeutics, Inc.<\/b><\/p>\n

\nHeadquartered in Houston, TX, Coya Therapeutics, Inc. (Nasdaq: COYA) is a clinical-stage biotechnology company developing proprietary treatments focused on the biology and potential therapeutic advantages of regulatory T cells (\u201cTregs\u201d) to target systemic inflammation and neuroinflammation. Dysfunctional Tregs underlie numerous conditions, including neurodegenerative, metabolic, and autoimmune diseases. This cellular dysfunction may lead to sustained inflammation and oxidative stress resulting in lack of homeostasis of the immune system.<\/p>\n

\nCoya\u2019s investigational product candidate pipeline leverages multiple therapeutic modalities aimed at restoring the anti-inflammatory and immunomodulatory functions of Tregs. Coya\u2019s therapeutic platforms include Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.<\/p>\n

\nFor more information about Coya, please visit www.coyatherapeutics.com<\/a><\/p>\n

About COYA 302<\/b><\/p>\n

\nCOYA 302 is an investigational and proprietary biologic combination therapy with a dual immunomodulatory mechanism of action intended to enhance the anti-inflammatory function of regulatory T cells (Tregs) and suppress the inflammation produced by activated monocytes and macrophages. COYA 302 comprises proprietary low dose interleukin-2 (LD IL-2) and CTLA-4 Ig and is being developed for subcutaneous administration for the treatment of patients with ALS. These mechanisms may have additive or synergistic effects.<\/p>\n

\nCoya is currently conducting the ALSTARS Trial, a Phase 2, randomized, multi-center, double-blind, placebo-controlled study to evaluate the efficacy and safety of COYA 302 for the treatment of ALS (Identifier: NCT07161999<\/a>).<\/p>\n

\nCOYA 302 is an investigational product not yet approved by the FDA or any other regulatory agency.<\/p>\n

Forward-Looking Statements<\/b><\/p>\n

\nThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this press release that are not statements of historical fact are forward-looking statements. Such forward-looking statements include, without limitation, statements regarding: expectations of Coya Therapeutics, Inc. (the \u201cCompany\u201d) regarding the potential benefits, effectiveness and safety of its product candidates; the significance and potential benefits associated with the FDA\u2019s Fast Track designation for COYA 302; the Company\u2019s ability to advance its product candidates through the preclinical and clinical development processes; the Company\u2019s expectations regarding, quality, timing and availability of data from the Company\u2019s clinical trials; the timing of announcements, updates and results of the Company\u2019s clinical trials and related data; the Company\u2019s future results of operations and financial position, including cash runway; and the potential therapeutic benefits and economic value of the Company\u2019s product candidates. These forward-looking statements are based on the beliefs of the management of the Company as well as assumptions made by and information currently available to the Company. Such statements reflect the current views of the Company with respect to future events and are subject to known and unknown risks and uncertainties. In light of these risks and uncertainties, the events or circumstances referred to in the forward-looking statements may not occur. These and other factors that may cause the Company\u2019s actual results to differ from current expectations are discussed in the Company\u2019s filings with the Securities and Exchange Commission (the \u201cSEC\u201d), including the section titled \u201cRisk Factors\u201d in the Company\u2019s Annual Report on Form 10-K for the year ended December 31, 2025. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date this press release is given. Except as required by law, the Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20260527446509\/en\/<\/a><\/span><\/p>\n

Investor Contact
\n<\/b>
David Snyder, CFO
\n
david@coyatherapeutics.com<\/a><\/p>\n

Media Contacts
\n<\/b>
Russo Partners
\n
David Schull
\n
David.Schull@russopartnersllc.com
\n<\/a>
858-717-2310<\/p>\n

\nRachelle Babb
\n
rachelle.babb@russopartnersllc.com
\n<\/a>
929-325-7559<\/p>\n

KEYWORDS:<\/b> Texas United States North America<\/p>\n

INDUSTRY KEYWORDS:<\/b> Biotechnology General Health Other Health Health Pharmaceutical<\/p>\n

MEDIA:<\/b><\/p>\n\n\n\n\n
Logo<\/b><\/font><\/td>\n<\/tr>\n
\"Logo\"<\/td>\n<\/tr>\n
<\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

Coya Therapeutics to Present ALSTARS Trial Design at the 5th ALS Drug Development Summit HOUSTON–(BUSINESS WIRE)–Coya Therapeutics, Inc. (NASDAQ: COYA) (\u201cCoya\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in patients with neurodegenerative disorders, announces that the Company will present an overview of the ongoing ALSTARS trial, outlining its design and approach to targeting neuroinflammation, at the 5th ALS Drug Development Summit which will take place June 2\u20134, 2026, in Boston, MA. The details for the poster presentation, which will be presented by Tyrell Simkins, D.O., Ph.D., Senior Director, Clinical Development, are below: Poster Title: ALSTARS: A Precision Immunomodulatory Phase 2 Trial of COYA 302 Targeting Regulatory T Cells and Neuroinflammation in ALS … <\/p>\n

Continue reading “Coya Therapeutics to Present ALSTARS Trial Design at the 5th ALS Drug Development Summit”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-967339","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nCoya Therapeutics to Present ALSTARS Trial Design at the 5th ALS Drug Development Summit - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/coya-therapeutics-to-present-alstars-trial-design-at-the-5th-als-drug-development-summit\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Coya Therapeutics to Present ALSTARS Trial Design at the 5th ALS Drug Development Summit - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Coya Therapeutics to Present ALSTARS Trial Design at the 5th ALS Drug Development Summit HOUSTON–(BUSINESS WIRE)–Coya Therapeutics, Inc. (NASDAQ: COYA) (\u201cCoya\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in patients with neurodegenerative disorders, announces that the Company will present an overview of the ongoing ALSTARS trial, outlining its design and approach to targeting neuroinflammation, at the 5th ALS Drug Development Summit which will take place June 2\u20134, 2026, in Boston, MA. The details for the poster presentation, which will be presented by Tyrell Simkins, D.O., Ph.D., Senior Director, Clinical Development, are below: Poster Title: ALSTARS: A Precision Immunomodulatory Phase 2 Trial of COYA 302 Targeting Regulatory T Cells and Neuroinflammation in ALS … Continue reading "Coya Therapeutics to Present ALSTARS Trial Design at the 5th ALS Drug Development Summit"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/coya-therapeutics-to-present-alstars-trial-design-at-the-5th-als-drug-development-summit\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-27T12:04:39+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260527446509r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/coya-therapeutics-to-present-alstars-trial-design-at-the-5th-als-drug-development-summit\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/coya-therapeutics-to-present-alstars-trial-design-at-the-5th-als-drug-development-summit\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Coya Therapeutics to Present ALSTARS Trial Design at the 5th ALS Drug Development Summit\",\"datePublished\":\"2026-05-27T12:04:39+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/coya-therapeutics-to-present-alstars-trial-design-at-the-5th-als-drug-development-summit\\\/\"},\"wordCount\":776,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/coya-therapeutics-to-present-alstars-trial-design-at-the-5th-als-drug-development-summit\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20260527446509r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/coya-therapeutics-to-present-alstars-trial-design-at-the-5th-als-drug-development-summit\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/coya-therapeutics-to-present-alstars-trial-design-at-the-5th-als-drug-development-summit\\\/\",\"name\":\"Coya Therapeutics to Present ALSTARS Trial Design at the 5th ALS Drug Development Summit - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/coya-therapeutics-to-present-alstars-trial-design-at-the-5th-als-drug-development-summit\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/coya-therapeutics-to-present-alstars-trial-design-at-the-5th-als-drug-development-summit\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20260527446509r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2026-05-27T12:04:39+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/coya-therapeutics-to-present-alstars-trial-design-at-the-5th-als-drug-development-summit\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/coya-therapeutics-to-present-alstars-trial-design-at-the-5th-als-drug-development-summit\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/coya-therapeutics-to-present-alstars-trial-design-at-the-5th-als-drug-development-summit\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20260527446509r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20260527446509r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/coya-therapeutics-to-present-alstars-trial-design-at-the-5th-als-drug-development-summit\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Coya Therapeutics to Present ALSTARS Trial Design at the 5th ALS Drug Development Summit\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Coya Therapeutics to Present ALSTARS Trial Design at the 5th ALS Drug Development Summit - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/coya-therapeutics-to-present-alstars-trial-design-at-the-5th-als-drug-development-summit\/","og_locale":"en_US","og_type":"article","og_title":"Coya Therapeutics to Present ALSTARS Trial Design at the 5th ALS Drug Development Summit - Market Newsdesk","og_description":"Coya Therapeutics to Present ALSTARS Trial Design at the 5th ALS Drug Development Summit HOUSTON–(BUSINESS WIRE)–Coya Therapeutics, Inc. (NASDAQ: COYA) (\u201cCoya\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in patients with neurodegenerative disorders, announces that the Company will present an overview of the ongoing ALSTARS trial, outlining its design and approach to targeting neuroinflammation, at the 5th ALS Drug Development Summit which will take place June 2\u20134, 2026, in Boston, MA. The details for the poster presentation, which will be presented by Tyrell Simkins, D.O., Ph.D., Senior Director, Clinical Development, are below: Poster Title: ALSTARS: A Precision Immunomodulatory Phase 2 Trial of COYA 302 Targeting Regulatory T Cells and Neuroinflammation in ALS … Continue reading \"Coya Therapeutics to Present ALSTARS Trial Design at the 5th ALS Drug Development Summit\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/coya-therapeutics-to-present-alstars-trial-design-at-the-5th-als-drug-development-summit\/","og_site_name":"Market Newsdesk","article_published_time":"2026-05-27T12:04:39+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260527446509r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/coya-therapeutics-to-present-alstars-trial-design-at-the-5th-als-drug-development-summit\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/coya-therapeutics-to-present-alstars-trial-design-at-the-5th-als-drug-development-summit\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Coya Therapeutics to Present ALSTARS Trial Design at the 5th ALS Drug Development Summit","datePublished":"2026-05-27T12:04:39+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/coya-therapeutics-to-present-alstars-trial-design-at-the-5th-als-drug-development-summit\/"},"wordCount":776,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/coya-therapeutics-to-present-alstars-trial-design-at-the-5th-als-drug-development-summit\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260527446509r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/coya-therapeutics-to-present-alstars-trial-design-at-the-5th-als-drug-development-summit\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/coya-therapeutics-to-present-alstars-trial-design-at-the-5th-als-drug-development-summit\/","name":"Coya Therapeutics to Present ALSTARS Trial Design at the 5th ALS Drug Development Summit - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/coya-therapeutics-to-present-alstars-trial-design-at-the-5th-als-drug-development-summit\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/coya-therapeutics-to-present-alstars-trial-design-at-the-5th-als-drug-development-summit\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260527446509r1&sid=flmnd&distro=nx&lang=en","datePublished":"2026-05-27T12:04:39+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/coya-therapeutics-to-present-alstars-trial-design-at-the-5th-als-drug-development-summit\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/coya-therapeutics-to-present-alstars-trial-design-at-the-5th-als-drug-development-summit\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/coya-therapeutics-to-present-alstars-trial-design-at-the-5th-als-drug-development-summit\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260527446509r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260527446509r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/coya-therapeutics-to-present-alstars-trial-design-at-the-5th-als-drug-development-summit\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Coya Therapeutics to Present ALSTARS Trial Design at the 5th ALS Drug Development Summit"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/967339","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=967339"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/967339\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=967339"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=967339"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=967339"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}